- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00642057
Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements (TBZ)
March 22, 2023 updated by: Joseph Jankovic
Compassionate Use of Tetrabenazine in the Treatment of Hyperkinesias
Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161).
The cost of the drug is passed on to the patient.
The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Detailed Description
The purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Study Type
Expanded Access
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rory D Mahabir, MBA
- Phone Number: 713-798-5989
- Email: rory.mahabir@bcm.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment.
- Willing to sign informed consent.
- Willing to comply with procedures required as part of this study.
Exclusion Criteria:
- Those subjects unwilling to comply with study requirements.
- Subjects unable to give informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
December 28, 2007
First Submitted That Met QC Criteria
March 21, 2008
First Posted (Estimate)
March 24, 2008
Study Record Updates
Last Update Posted (Actual)
March 24, 2023
Last Update Submitted That Met QC Criteria
March 22, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Hyperkinesis
- Movement Disorders
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Adrenergic Uptake Inhibitors
- Tetrabenazine
Other Study ID Numbers
- H-721
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperkinetic Movement Disorders
-
Assistance Publique - Hôpitaux de ParisRecruitingSpinocerebellar Ataxias | Inherited Movement Disorders | Hyperkinetic DisordersFrance
-
National Institute of Neurological Disorders and...TerminatedHealthy Volunteer | Tourette Syndrome | Movement DisorderUnited States
-
University Medical Centre LjubljanaRecruitingTremor | SMA | MND (Motor Neurone DIsease) | Involuntary MovementsSlovenia
-
Aarhus University HospitalTakedaActive, not recruitingAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Hyperkinetic DisorderDenmark
-
Heidelberg UniversityEsslingen University of Applied Sciences; Leibniz Institute for Research and...RecruitingDepressive Disorder | Anxiety Disorder | Hyperkinetic DisorderGermany
-
Far Eastern Memorial HospitalNational Taiwan University Hospital; Academia Sinica, TaiwanUnknownAttention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Hyperkinetic SyndromeTaiwan
-
HaEmek Medical Center, IsraelCompletedEyelid Movement Disorders
-
University of ZurichCompleted
-
University of Southern CaliforniaCompletedMovement Disorders in Children
-
The Cleveland ClinicActive, not recruitingFunctional Movement DisorderUnited States
Clinical Trials on tetrabenazine
-
Dr. Reddy's Laboratories LimitedCompleted
-
Prestwick PharmaceuticalsCompletedHuntington's Disease
-
New York Medical CollegeCompleted
-
Bausch Health Americas, Inc.Withdrawn
-
Dr. Reddy's Laboratories LimitedCompleted
-
Centre Hospitalier Universitaire, AmiensCompleted
-
William Ondo, MDH. Lundbeck A/SRecruitingHuntington's DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedHuntington DiseaseFrance
-
Neurocrine BiosciencesCompletedTardive DyskinesiaUnited States, Puerto Rico
-
Neurocrine BiosciencesCompletedTardive DyskinesiaUnited States, Puerto Rico